Concordance Between ER, PR, HER2 neu Receptors Before and After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar. 65(2): 87–108. TorreLA BrayF SiegelRL FerlayJ Lortet-TieulentJ JemalA Global cancer statistics, 2012 CA Cancer J Clin 2015 Mar. 65 2 87 108 10.3322/caac.2126225651787 Search in Google Scholar

[2] Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis. J Natl Cancer Inst. 2005; 97: 188–194. MauriD PavlidisN IoannidisJPA Neoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis J Natl Cancer Inst. 2005 97 188 194 10.1093/jnci/dji02115687361 Search in Google Scholar

[3] Bartlett JM1, Brookes CL, Robson T, van de Velde CJ, Billingham LJ, Campbell FM, et al. Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol. 2011; 29: 1531–1538. BartlettJM1 BrookesCL RobsonT van de VeldeCJ BillinghamLJ CampbellFM Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial J Clin Oncol. 2011 29 1531 1538 10.1200/JCO.2010.30.3677308297321422407 Search in Google Scholar

[4] Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011; 29: 594–598. ZhangN MoranMS HuoQ HafftyBG YangQ The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis Cancer Invest. 2011 29 594 598 10.3109/07357907.2011.62191322011281 Search in Google Scholar

[5] Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer. 2005; 92: 147–155. BurcombeRJ MakrisA RichmanPI DaleyFM NobleS PittamM Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer. 2005 92 147 155 10.1038/sj.bjc.6602256236175015611798 Search in Google Scholar

[6] Shet T, Agrawal A, Chinoy R, Havaldar R, Parmar V, Badwe R. Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy—implications for a pathologist. Breast J. 2007; 13: 457–464. ShetT AgrawalA ChinoyR HavaldarR ParmarV BadweR Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy—implications for a pathologist Breast J. 2007 13 457 464 10.1111/j.1524-4741.2007.00465.x17760666 Search in Google Scholar

[7] Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012; 19: 3002–3011. ChenS ChenCM YuKD ZhouRJ ShaoZM Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer Ann Surg Oncol. 2012 19 3002 3011 10.1245/s10434-012-2318-222437200 Search in Google Scholar

[8] HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM Breast Cancer. 2005; 12(4): 294–8. HER-2/neu expression in locally advanced breast carcinomas: pre-and post-neoadjuvant chemotherapy QuddusRM SungJC ZhangC PasquerielloT EklundM SteinhoffMM Breast Cancer 2005 12 4 294 8 10.2325/jbcs.12.29416286910 Search in Google Scholar

[9] Giuliano AE1, Connolly JL2, Edge SB3, Mittendorf EA4, Rugo HS5, Solin LJ6, et al. (2017) Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 290–303. GiulianoAE1 ConnollyJL2 EdgeSB3 MittendorfEA4 RugoHS5 SolinLJ6 2017 Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual CA Cancer J Clin 67 290 303 10.3322/caac.2139328294295 Search in Google Scholar

[10] Elston CW, Ellis IO (2002) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403–410. ElstonCW EllisIO 2002 Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 403 410 10.1111/j.1365-2559.1991.tb00229.x1757079 Search in Google Scholar

[11] van de Ven S, Smit VT, Dekker TJ, Nortier JW, Kroep JR. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011; 37: 422–430. van de VenS SmitVT DekkerTJ NortierJW KroepJR Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer Cancer Treat Rev. 2011 37 422 430 10.1016/j.ctrv.2010.11.00621177040 Search in Google Scholar

[12] Zhang N, Moran MS, Huo Q, Haffty BG, Yang Q. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis. Cancer Invest. 2011; 29: 594–598. ZhangN MoranMS HuoQ HafftyBG YangQ The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy: a meta-analysis Cancer Invest. 2011 29 594 598 10.3109/07357907.2011.62191322011281 Search in Google Scholar

[13] Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest. 2011; 121: 3789–3796. BertosNR ParkM Breast cancer - one term, many entities? J Clin Invest. 2011 121 3789 3796 10.1172/JCI57100319546521965335 Search in Google Scholar

[14] Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429–4434. DentR TrudeauM PritchardKI HannaWM KahnHK SawkaCA Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res. 2007 13 4429 4434 10.1158/1078-0432.CCR-06-304517671126 Search in Google Scholar

[15] Hirata T1, Shimizu C, Yonemori K, Hirakawa A, Kouno T, Tamura K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer. Br J Cancer. 2009; 101: 1529–1536. doi: 10.1038/sj.bjc.6605360. HirataT1 ShimizuC YonemoriK HirakawaA KounoT TamuraK Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer Br J Cancer 2009 101 1529 1536 10.1038/sj.bjc.6605360 277852519809429 Open DOISearch in Google Scholar

[16] Xi Jin1, Yi-Zhou Jiang1, Sheng Chen1, Ke-Da Yu1, Zhi-Ming Shao1, Gen-Hong Di. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study. Oncotarget, Vol. 6, No. 11, 2015. Jin1Xi Jiang1Yi-Zhou Chen1Sheng Yu1Ke-Da Shao1Zhi-Ming DiGen-Hong Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study Oncotarget 6 11 2015 10.18632/oncotarget.3292449624225826079 Search in Google Scholar

[17] Chen S, Chen CM, Yu KD, Zhou RJ, Shao ZM. Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer. Ann Surg Oncol. 2012; 19: 3002–3011. doi: 10.1245/s10434-012-2318-2. ChenS ChenCM YuKD ZhouRJ ShaoZM Prognostic value of a positive-to-negative change in hormone receptor status after neoadjuvant chemotherapy in patients with hormone receptor-positive breast cancer Ann Surg Oncol. 2012 19 3002 3011 10.1245/s10434-012-2318-2 22437200 Open DOISearch in Google Scholar

[18] Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996; 14: 1718–1729. BinesJ OleskeDM CobleighMA Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer J Clin Oncol. 1996 14 1718 1729 10.1200/JCO.1996.14.5.17188622093 Search in Google Scholar

[19] Rose DP, Davis TE. Effects of Adjuvant Chemohormonal Therapy on the Ovarian and Adrenal Function of Breast Cancer Patients. Cancer Res. 1980; 40: 4037–4047. RoseDP DavisTE Effects of Adjuvant Chemohormonal Therapy on the Ovarian and Adrenal Function of Breast Cancer Patients Cancer Res. 1980 40 4037 4047 Search in Google Scholar

[20] Niikura N, Tomotaki A, Miyata H, Iwamoto T, Kawai M, Anan K, et al. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry. Ann Oncol. 2016; 27: 480–487. doi: 10.1093/annonc/mdv611. NiikuraN TomotakiA MiyataH IwamotoT KawaiM AnanK Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry Ann Oncol. 2016 27 480 487 10.1093/annonc/mdv611 26704052 Open DOISearch in Google Scholar

[21] Matsubara N1, Mukai H, Masumoto M, Sasaki M, Naito Y, Fujii S, Wada N. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR. Breast Cancer Res Treat. 2014; 147: 95–102. doi: 10.1007/s10549-014-3084-6. MatsubaraN1 MukaiH MasumotoM SasakiM NaitoY FujiiS WadaN Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR Breast Cancer Res Treat 2014 147 95 102 10.1007/s10549-014-3084-6 25106660 Open DOISearch in Google Scholar

[22] Matsubara N, Mukai H, Fujii S, Wada N. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat. 2013; 137: 203–212. doi: 10.1007/s10549-012-2344-6. MatsubaraN MukaiH FujiiS WadaN Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer Breast Cancer Res Treat 2013 137 203 212 10.1007/s10549-012-2344-6 23184081 Open DOISearch in Google Scholar